dc.creatorCardoso Cúneo, Jorge Eduardo Carlos
dc.creatorNievas, S.
dc.creatorPereira, M.
dc.creatorSchwint, Amanda Elena
dc.creatorTrivillin, Verónica Andrea
dc.creatorPozzi, Emiliano César Cayetano
dc.creatorHeber, Elisa Mercedes
dc.creatorMonti Hughes, Andrea
dc.creatorSanchez, P.
dc.creatorBumaschny, E.
dc.creatorItoiz, María Elina
dc.creatorLiberman, Susana Alcira
dc.date.accessioned2022-05-12T11:29:41Z
dc.date.accessioned2022-10-15T10:17:22Z
dc.date.available2022-05-12T11:29:41Z
dc.date.available2022-10-15T10:17:22Z
dc.date.created2022-05-12T11:29:41Z
dc.date.issued2009-07
dc.identifierCardoso Cúneo, Jorge Eduardo Carlos; Nievas, S.; Pereira, M.; Schwint, Amanda Elena; Trivillin, Verónica Andrea; et al.; Boron biodistribution study in colorectal liver metastases patients in Argentina; Pergamon-Elsevier Science Ltd; Applied Radiation and Isotopes; 67; 7-2009; 76-79
dc.identifier0969-8043
dc.identifierhttp://hdl.handle.net/11336/157329
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4374699
dc.description.abstractEx-situ BNCT for multifocal unresectable liver metastases employing whole or partial autograft techniques requires knowledge of boron concentrations in healthy liver and metastases following perfusion and immersion in Wisconsin solution (W), the procedure employed for organ preservation during ex-situ irradiation. Measurements of boron concentration in blood, liver and metastases following an intravenous infusion of BPA-F in five colorectal liver metastases patients scheduled for surgery were performed. Tissue samples were evaluated for boron content pre and post perfusion and immersion in W. Complementary histological studies were performed. The data showed a dose-dependent BPA uptake in liver, a boron concentration ratio liver/blood close to 1 and a wide spread in the metastases/liver concentration ratios in the range 0.8-3.6, partially attributable to histological variations between samples. Based on the boron concentrations and dose considerations (liver < or =15 Gy-Eq and tumor> or =40 Gy-Eq) at the RA-3 thermal neutron facility (mean flux of about (6+/-1) x 10(9) n cm(-2)s(-1)), ex-situ treatment of liver metastases at RA-3 would be feasible.
dc.languageeng
dc.publisherPergamon-Elsevier Science Ltd
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S0969804309002504
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.apradiso.2009.03.021
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectBoron neutron capture therapy
dc.subjectUnresectable colorectal liver metastases
dc.subject10B biodistribution
dc.subjectHepatic autograft
dc.titleBoron biodistribution study in colorectal liver metastases patients in Argentina
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución